Search
Now showing items 1-8 of 8
Impact of a pharmacist-delivered discharge and follow-up intervention for patients with acute coronary syndromes in Qatar: A study protocol for a randomised controlled trial
(
BMJ Publishing Group
, 2016 , Article)
Introduction: Acute coronary syndrome (ACS) is one of the leading causes of morbidity and mortality worldwide. Secondary cardiovascular risk reduction therapy (consisting of an aspirin, a ?-blocker, an ACE inhibitor or an ...
Effectiveness of a structured pharmacist-delivered intervention for patients post-acute coronary syndromes on all-cause hospitalizations and cardiac-related hospital readmissions: a prospective quasi-experimental study
(
Springer
, 2023 , Article)
Background: Acute coronary syndrome (ACS) is a leading cause of mortality and morbidity in Qatar and globally. Aim: The primary objective of the study was to evaluate the effectiveness of a structured clinical pharmacist-delivered ...
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction
(
Elsevier
, 2022 , Article)
Although previous cost‐effectiveness evaluations of sacubitril/valsartan have demonstrated cardiovascular and economic benefits in heart failure patients with reduced ejection fraction (HFrEF), whether sacubitril/valsartan ...
Has low-dose intracoronary thrombolysis gained ground in primary percutaneous intervention?
(
SAGE
, 2022 , Article)
Reducing thrombus burden would improve patient’s outcomes. Low-dose intracoronary thrombolytic agent administration has been considered to improve myocardial microcirculation, cardiac function, and major adverse cardiovascular ...
Intracoronary pharmacological therapy versus aspiration thrombectomy in STEMI (IPAT-STEMI): A systematic review and meta-analysis of randomized trials
(
Public Library of Science
, 2022 , Article)
Background Thrombus load in STEMI patients remains a challenge in practice. It aggravates coronary obstruction leading to impaired myocardial perfusion, worsened cardiac function, and adverse clinical outcomes. Various ...
Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis
(
Springer Nature
, 2024 , Article)
Objective: This study aimed to assess the overall economic impact of clinical pharmacist interventions in the neonatal ICU (NICU) in Qatar. Methods: A retrospective review of neonates’ records was performed over a 3-month ...
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis
(
Elsevier Inc.
, 2024 , Article)
Introduction: While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). ...
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
(
Taylor & Francis
, 2024 , Article)
Aim: To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) patients from the ...